Form 8-K - Current report:
SEC Accession No. 0001193125-25-159017
Filing Date
2025-07-15
Accepted
2025-07-15 07:05:21
Documents
16
Period of Report
2025-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d99462d8k.htm   iXBRL 8-K 26475
2 EX-1.1 d99462dex11.htm EX-1.1 187290
3 EX-5.1 d99462dex51.htm EX-5.1 13283
7 GRAPHIC g99462g0714094110299.jpg GRAPHIC 1690
8 GRAPHIC g99462g0714095058278.jpg GRAPHIC 2373
  Complete submission text file 0001193125-25-159017.txt   407965

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA inkt-20250715.xsd EX-101.SCH 2865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20250715_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20250715_pre.xml EX-101.PRE 11717
18 EXTRACTED XBRL INSTANCE DOCUMENT d99462d8k_htm.xml XML 3765
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 251123057
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)